Skip to Content
  • Arena, Lorcaserin, and the FDA

    I’ve been getting a lot of objections to my opinion on Arena’s obesity candidate lorcaserin. Specifically, the first level of the dispute seems to be whethe… Read More
  • Book Review Department

    For those who are interested, I have a review up at Nature Biotechnology of Reasonable Rx: Solving the Drug Price Crisis, a book that proposes an. . .interestin… Read More
  • Dendreon’s Revenge?

    Post updated below – DBL Dendreon is a company that’s really been through it, as have their investors. Many will remember the upheaval back in 2007… Read More
  • A DPP-IV Compound Makes It Through

    After talking the other week about the problems that Takeda has had with their DPP-IV inhibitor for diabetes, it now appears that AstraZeneca and Bristol-Myers… Read More
  • Takeda Gets A Surprise

    DPP-IV is short for “dipeptidylpeptidase IV”, understandably, and we need a good abbreviation for it. It’s an important enzyme target for diabetes therapy… Read More
  • Lilly Pays the Price

    Eli Lilly has been in trouble for some time now regarding off-label promotion of their antipsychotic Zyprexa – specifically, their sales reps seem to have gon… Read More
Page 23 of 24« First...10...2021222324